MGAM x PRKAB1

The goal of this clinical trial is to compare blood-sugar control and blood circulatory system risk-position in type 2 diabetes patients on voglibose versus those on glybenclamide when the two drugs are added to metformin because metformin alone is not controlling the blood-sugar well. The results of this trial will help in improving the health and treatment results of the type 2 diabetic patients.
The main question the trial aims to answer is whether there is a difference in blood-sugar and blood circulatory system treatment results between voglibose + metformin and glibenclamide + metformin treatment combinations.
Participants that agree to participate in the trial will be asked to provide a sample of blood so that the following measurable laboratory factors will be used to compare any differences in treatment results between the two treatment groups from the beginning to the end of the trial:
Total Cholesterol (TC),
Low Density Lipoproteins (LDL-c),
High Density Lipoproteins (HDL-c),
Fasting Triglycerides (FTG),
Fasting blood sugar (FBS),
Post prandial blood sugar (PPBG),
Glycated hemoglobin (HbA1c) correlated to hemoglobin level,
creatinine,
blood urea and
electrolytes (K+, Na+, Cl-).

The purpose of this research study is to test the safety and effectiveness of Seleno-L Methionine (SLM) when combined with the standard dose and schedule of Axitinib and Pembrolizumab in patients who have locally advanced or metastatic clear cell renal cell carcinoma (ccRCC).